Company intelligence / Profile preview
Shanghai Yuansong Biotechnology Co., Ltd.
Shanghai, Shanghai Shi, Chinayuansongbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
YSCH‑01 has demonstrated safety and preliminary efficacy in a Phase I investigator‑initiated trial for advanced solid tumors. The product uses a genetically modified oncolytic adenovirus to deliver therapeutic genes selectively to tumor cells. Early results show the approach was well tolerated with signs of antitumor activity in heavily pretreated patients.[6] Additional programs are at preclinical or early clinical stages.[3]
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic viruses (notably recombinant L-IFN adenovirus)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical partnerships publicly disclosed.
Beyond the preview
Go deeper on Shanghai Yuansong Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Yuansong Biotechnology Co., Ltd..